GameChanger Law Advisors advised Peptris Technologies on its licensing agreement with Revio Therapeutics for PEPR124 (RT001), an AI-discovered drug candidate for Duchenne Muscular Dystrophy (DMD).

The transaction team consisted of Samheeta Rao (Senior Partner) and Dia Shetty (Associate).

Under this deal, Peptris is licensing its preclinical-stage asset, PEPR124 (RT001), to Revio for further development in DMD, a rare genetic disorder with limited treatment options. The agreement will help Peptris expand its global biotech presence while accelerating AI-powered drug discovery. Revio will hold commercialisation rights for PEPR124 (RT001) in all markets except BRICS countries, which Peptris will retain.

According to reports, PEPR124 (RT001), discovered through Peptris’ AI-driven platform, has shown promising preclinical efficacy as a repurposed, mutation-agnostic, and safe therapeutic.

Peptris is an AI-powered preclinical drug discovery company. Peptris’ proprietary AI platform integrates unsupervised learning and generative AI to design optimized molecules, significantly reducing the need for wet lab testing. The automated platform streamlines this process, designing potent, safe, selective, and biologically active drug candidates. This marks India’s first AI-discovered drug candidate to be out-licensed, according to the company.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.